Maintenance Olaparib Rechallenge in Platinum-Sensitive Relapsed Ovarian Cancer
1. Median PFS was improved in the olaparib arm vs placebo, with an HR 0.57 in the BRCAm cohort and ...
Tag: brca
Cisplatin with Veliparib in BRCA Stratified Metastatic Triple-Negative Breast Cancer
1. There was some progression-free survival benefit in adding veliparib to cisplatin in patients who had homologous recombination DNA repair ...
Maintenance olaparib, compared with placebo, reduces the risk of disease progression in patients with advanced BRCA mutation ovarian cancer
1. Median progression-free survival was 56.0 months in the olaparib group and was 13.8 months in the placebo group. 2. ...
#VisualAbstract: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
1. This phase 3 trial of olaparib plus bevacizumab showed a significant progression-free survival benefit for ovarian cancer maintenance therapy. ...
Olaparib plus bevacizumab for ovarian cancer maintenance therapy
1. This phase 3 trial of olaparib plus bevacizumab showed a significant progression-free survival benefit for ovarian cancer maintenance therapy. ...
Normal tissue BRCA1 methylation associated with risk for high-grade ovarian cancer
1. BRCA1 promoter methylation in normal white blood cells (WBCs) was linked to risk for high-grade serous ovarian cancer (HGSOC). ...
Specific BRCA1/BRCA2 mutations linked to breast and ovarian cancer risk
1. Multiple breast cancer cluster regions (BCCRs) and ovarian cancer cluster regions (OCCRs) were identified in BRCA1 and BRCA2 genes ...
Olaparib monotherapy may be effective in advanced BRCA-associated cancers
1. Olaparib monotherapy was associated with prolonged tumor response rate in advanced BRCA1/2-associated breast, ovarian, pancreatic, and prostate cancers. 2. ...
Clinically undetectable ovarian and tubal tumors may be present in high-risk patients
1. A non-randomized control trial of 996 women at high risk for developing ovarian and tubal cancer found that 2.6% ...